Aug 5, 2026 04:05PM
May 6, 2026 04:05PM
Mar 23, 2026 08:30AM
Mar 23, 2026 08:30AM
Mar 18, 2026 07:34PM
Mar 18, 2026 07:34PM
Mar 10, 2026 12:08PM Jefferies Reiterates Buy Rating on Vaxcyte (PCVX): "adult PCV alone increasingly supports a materially higher long-term valuation"
Feb 24, 2026 04:05PM
Feb 11, 2026 04:05PM
Feb 11, 2026 04:05PM
Jan 22, 2026 05:00PM
Jan 6, 2026 08:18AM
Dec 21, 2025 08:00PM
Dec 8, 2025 07:00AM Vaxcyte begins phase 3 trial for VAX-31 pneumococcal vaccine
Dec 8, 2025 07:00AM
Oct 1, 2025 01:20PM
Oct 1, 2025 01:13PM
Sep 3, 2025 07:30AM
Sep 3, 2025 07:30AM
Aug 8, 2025 08:34AM
Aug 6, 2025 04:05PM Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vacci
May 7, 2025 04:01PM
Apr 22, 2025 07:22AM
Apr 1, 2025 05:07AM
Mar 31, 2025 10:04AM
Mar 31, 2025 07:00AM
Mar 31, 2025 07:00AM
Feb 25, 2025 04:01PM Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Feb 5, 2025 08:02AM
Feb 5, 2025 08:00AM
Dec 19, 2024 02:00PM
Dec 3, 2024 08:00AM
Nov 12, 2024 07:31AM
Nov 12, 2024 07:30AM
Nov 5, 2024 04:01PM Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
Sep 3, 2024 08:43AM
Sep 3, 2024 07:07AM
Jul 2, 2024 08:30AM
Mar 4, 2024 08:30AM
Feb 27, 2024 04:01PM
Jan 29, 2024 08:30AM
Jan 4, 2024 04:02PM Vaxcyte, Inc (PCVX) Provides Clinical and Regulatory Progress Update on Pneumococcal Conjugate Vaccine (PCV) Franchise
Jan 4, 2024 04:01PM
Dec 4, 2023 06:35PM
Nov 6, 2023 04:03PM
Oct 19, 2023 08:30AM
Aug 8, 2023 04:03PM
Jul 11, 2023 08:33AM
Jul 11, 2023 08:30AM Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
May 8, 2023 04:03PM

327,796 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All